UniProtKB/Swiss-Prot Q92530 : Variant p.Phe36Cys
Proteasome inhibitor PI31 subunit
Gene: PSMF1
Feedback ?
Variant information
Variant position:
36
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Phenylalanine (F) to Cysteine (C) at position 36 (F36C, p.Phe36Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and aromatic (F) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
36
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
271
The length of the canonical sequence.
Location on the sequence:
TCRQDALVCFLHWEVVTHGY
F GLGVGDQPGPNDKKSELLPA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human TCRQDALVCFLHWEVVTH-GYF GLGVGDQPG-PNDKKSELLPA
Mouse SCPQDALVCFLHWEVVTN-GYY ALGTGDQPG-PSDKKSELL
Rat TCPQDALVCFLHWEVVTN-GYY GLGTGDQPD-PNDKKSELL
Bovine TCAQDALVCFLHWEVVTH-GYY GLGAGDQPG-PNDKKSELL
Drosophila SKKSDLLIALVHFLLTKHYNFR CVGVGDDKTLPEEEGSELL
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 271
Proteasome inhibitor PI31 subunit
Region
2 – 150
Important for homodimerization and interaction with FBXO7
Beta strand
35 – 43
Literature citations
cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome.
McCutchen-Maloney S.L.; Matsuda K.; Shimbara N.; Binns D.D.; Tanaka K.; Slaughter C.A.; DeMartino G.N.;
J. Biol. Chem. 275:18557-18565(2000)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT CYS-36; FUNCTION; SUBUNIT;
Submission
Mural R.J.; Istrail S.; Sutton G.G.; Florea L.; Halpern A.L.; Mobarry C.M.; Lippert R.; Walenz B.; Shatkay H.; Dew I.; Miller J.R.; Flanigan M.J.; Edwards N.J.; Bolanos R.; Fasulo D.; Halldorsson B.V.; Hannenhalli S.; Turner R.; Yooseph S.; Lu F.; Nusskern D.R.; Shue B.C.; Zheng X.H.; Zhong F.; Delcher A.L.; Huson D.H.; Kravitz S.A.; Mouchard L.; Reinert K.; Remington K.A.; Clark A.G.; Waterman M.S.; Eichler E.E.; Adams M.D.; Hunkapiller M.W.; Myers E.W.; Venter J.C.;
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANT CYS-36;
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT CYS-36;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.